Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 3/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 3/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15345157 | 1.00 | DRD4 (0.43) | DRD4LRRK2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL15345158 | 1.00 | DRD4 (0.43) | DRD4LRRK2CYP2D6SLC6A2SLC6A4 | |
| SCHEMBL17547087 | 0.87 | DRD4 (0.42) | DRD4SIGMAR1PDE1CKDM1AKDM2B | |
| SCHEMBL17547107 | 0.87 | DRD4 (0.42) | DRD4SIGMAR1PDE1CKDM1AKDM2B | |
| SCHEMBL15341850 | 0.85 | DRD3 (0.50) | DRD4BRD4SIGMAR1PDE1CKDM1A | |
| SCHEMBL15341844 | 0.85 | DRD3 (0.50) | DRD4BRD4SIGMAR1PDE1CKDM1A | |
| SCHEMBL15341843 | 0.85 | DRD3 (0.50) | DRD4BRD4SIGMAR1PDE1CKDM1A | |
| SCHEMBL15334030 | 0.78 | DRD2 (0.46) | DRD3 | |
| SCHEMBL15317630 | 0.76 | QDPR (0.50) | DRD4SLC6A4BRD4SIGMAR1PDE1C | |
| SCHEMBL15345135 | 0.76 | PDE1C (0.42) | DRD4SIGMAR1PDE1CKDM1AKDM2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3070081-B1 | BENZOTHIAZOL-6-YL ACETIC ACID DERIVATIVES AND THEIR USE FOR TREATING AN HIV INFECTION | GILEAD SCIENCES INC (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2016-01-21 | — | — | US | disclosed |
| US-8987250-B2 | Therapeutic compounds | GILEAD SCIENCES, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2013-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160015690-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | DRD4 3049/4885LRRK2 690/4885CYP2D6 302/4885 |
| US-20130281433-A1 | THERAPEUTIC COMPOUNDS | NQO1, HAVCR2, CCR5 | DRD4 3049/4885LRRK2 690/4885CYP2D6 302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.